Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2023-05-22 Director's Dealing
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2023-05-22 English
FORM 4
Director's Dealing
2023-05-12 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2023, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2023. The text explicitly states that the press release is furnished as an exhibit and that the information is being furnished, not filed, and is not the full financial report itself. The document length is 3520 characters, which is relatively short and consistent with an announcement rather than a full earnings report. The content corresponds to an initial announcement of quarterly financial results, which aligns with the definition of an Earnings Release (ER). Therefore, the document should be classified as an Earnings Release (ER).
2023-05-10 English
FORM 10-Q
Interim / Quarterly Report Q1 2023
2023-05-10 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated May 9, 2023. It announces the issuance of a U.S. patent and includes a press release as an exhibit. The content is an event announcement rather than a financial report or detailed filing. The document length is 3570 characters, which is relatively short and mainly serves to notify the market of a specific event (patent issuance). There are no financial statements or detailed financial data included. This fits the profile of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories like earnings release, annual report, or management information. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-05-09 English
FORM 10-K/A
Annual Report FY 2022
2023-05-01 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.